Dear Editor, We thank the authors for their letter, which highlights the important issue of the high prevalence of viral hepatitis within East Asia and the common coexistence of this condition with nonalcoholic fatty liver disease (NAFLD) within this population [1] . We agree with the authors that obesity is less of an issue in East Asia, and that NAFLD in East Asia may occur in Blean^subjects. However, it is important to note that the prevalence of overweight and obesity has nearly trebled in adults from China in the last three decades [2] . Moreover, the definition of obesity in Asia has now been proposed to be a body mass index >25 kg/m 2 . This is considerably lower than that used in Western countries and is due to the higher risks of developing features of the metabolic syndrome associated with overweight and obesity in Asia, at lower weight thresholds [2] .
In our study, we observed rapid improvements in NAFLD with modest weight loss in the obese [3] . This study population, and general demographics in Australia, more accurately reflects those of Western countries and of European descent. Furthermore, consistent with many current publications in NAFLD, we have excluded participants based on positive viral hepatitis status. We agree that these findings may not be applicable to a mixed etiology cohort, as this is often seen in the Asian setting. Interpretation of ALT may indeed be more challenging in this scenario.
Further research into the effects of weight loss on NAFLD in the setting of concurrent viral hepatitis, particularly in subjects from Asia, is an area of research that is of great importance given the large population affected from Eastern countries.
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